Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings"
- PMID: 33892009
- DOI: 10.1016/j.jhep.2021.04.017
Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings"
Keywords: DAAs; G/P; GT; HCC; HCV; Hepatitis C Virus; RASs; RBV; SOF; direct-acting antivirals; genotype; glecaprevir/pibrentasvir; hepatocellular carcinoma; rescue therapy; resistance-associated substitutions; ribavirin; sofosbuvir.
Conflict of interest statement
Conflict of interest Julia Dietz: Research support from Gilead. Christoph Sarrazin: Speaking and/or consulting fees: Abbvie, Gilead, Merck/MSD, Research support: Abbvie, Gilead. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.J Hepatol. 2021 Apr;74(4):801-810. doi: 10.1016/j.jhep.2020.11.017. Epub 2020 Nov 19. J Hepatol. 2021. PMID: 33220331
-
Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.J Hepatol. 2021 Jul;75(1):251-254. doi: 10.1016/j.jhep.2021.02.024. Epub 2021 Feb 27. J Hepatol. 2021. PMID: 33652031 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
